A Retrospective Study to Evaluate the Effectiveness and Benefit of onabotulinumtoxinA in Patients With Chronic Migraines

Allergan

Status: Completed

Conditions: Chronic Migraine, Headaches

Treatments: Biological: onabotulinumtoxinA

Study type: Observational

Funder types: Industry

Identifiers

NCT01749410

GMA-BTX-CM-12-491

Details and patient eligibility

About

This study will evaluate the effectiveness and benefit of treatment with onabotulinumtoxinA in Chronic Migraine patients who have received a minimum of 7 treatment cycles.

Enrollment: 33 patients

Sex: All

Ages: 18 to 65 years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• 15 or more headache days over a 30 day period
• A minimum of 7 treatment cycles with onabotulinumtoxinA

Exclusion criteria

• Any treatment cycle dose of onabotulinumtoxinA greater than 200 units

Trial design

33 participants in 1 patient group

All participants

Description:

Previous treatment with onabotulinumtoxinA for Chronic Migraine based on retrospective medical record review.

Treatment:

Biological: onabotulinumtoxinA